“CD20×CD3 Bispecific Antibodies in Relapsed Refractory B-Cell Lymphomas: Recent Phase III Evidence Durability, and Safety”. 2026. Journal of Medical Sciences 21 (2): 30-35. https://doi.org/10.51984/szn7cg42.